Number of eligible patients: CDEC discussed the uncertainty in the amount of sufferers with moderately extreme to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be categorised as acquiring delicate or reasonable condition might have a severe